Daewoong Pharmaceutical announced on February 3 that its botulinum toxin "Nabota (US export name: Jeuveau)" had obtained positive interim results for long-lasting effects in high-dose clinical trials for patients with glabellar wrinkles.
Daewoong Pharmaceutical's partner for cosmetic indications in the US, Evolus, administered high-dose Jeuveau (40 units) at the International Society of Cosmetic Surgery (IMCAS) held in Paris, France on January 28th and observed the effect of improving frown wrinkles for 6 months. "Extra Strength" Announced the interim results of the phase 2 clinical trial.
This clinical trial was conducted from March last year on 150 patients under the age of 65 with moderate to severe glabellar wrinkles.
Evolus said in an ongoing study that a long-lasting effect of 6 months or 26 weeks was confirmed when a high dose of 40 units of Jeuveau was administered, and safety was proven without serious side effects.
In this clinical trial, persistence was evaluated at 30-day cycles for 3 days, 7 days, and 12 months. This was evaluated by deriving the interim analysis results of the evaluation variables, the Glabellar Line Scale (GLS) and the Global Aesthetic Improvement Scale (GAIS).
Studies have shown that 50% of patients after the high-dose Jeuveau treatment took approximately 26 weeks to return to their pre-procedure condition.
This clinical trial demonstrated that high-dose Jeuveau offers an option for long-cycle treatment. This is expected to lead to increased convenience and preference according to the decrease in the number of clinic visits by patients.
